These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 25456365)

  • 1. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
    Sestak I; Singh S; Cuzick J; Blake GM; Patel R; Gossiel F; Coleman R; Dowsett M; Forbes JF; Howell A; Eastell R
    Lancet Oncol; 2014 Dec; 15(13):1460-1468. PubMed ID: 25456365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
    Markopoulos C; Tzoracoleftherakis E; Polychronis A; Venizelos B; Dafni U; Xepapadakis G; Papadiamantis J; Zobolas V; Misitzis J; Kalogerakos K; Sarantopoulou A; Siasos N; Koukouras D; Antonopoulou Z; Lazarou S; Gogas H
    Breast Cancer Res; 2010; 12(2):R24. PubMed ID: 20398352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
    Van Poznak C; Hannon RA; Mackey JR; Campone M; Apffelstaedt JP; Clack G; Barlow D; Makris A; Eastell R
    J Clin Oncol; 2010 Feb; 28(6):967-75. PubMed ID: 20065185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
    Goss PE; Hershman DL; Cheung AM; Ingle JN; Khosla S; Stearns V; Chalchal H; Rowland K; Muss HB; Linden HM; Scher J; Pritchard KI; Elliott CR; Badovinac-Crnjevic T; St Louis J; Chapman JA; Shepherd LE
    Lancet Oncol; 2014 Apr; 15(4):474-82. PubMed ID: 24636210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
    Välimäki MJ; Farrerons-Minguella J; Halse J; Kröger H; Maroni M; Mulder H; Muñoz-Torres M; Sääf M; Snorre Øfjord E
    Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
    Sergi G; Pintore G; Falci C; Veronese N; Berton L; Perissinotto E; Basso U; Brunello A; Monfardini S; Manzato E; Coin A
    J Bone Miner Metab; 2012 Jul; 30(4):461-7. PubMed ID: 22160398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia.
    Sestak I; Blake GM; Patel R; Coleman RE; Cuzick J; Eastell R
    Bone; 2019 Jul; 124():83-88. PubMed ID: 31028957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
    Markopoulos C; Tzoracoleftherakis E; Koukouras D; Venizelos B; Zobolas V; Misitzis J; Xepapadakis G; Gogas H
    J Cancer Res Clin Oncol; 2012 Sep; 138(9):1569-77. PubMed ID: 22552718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
    Cuzick J; Sestak I; Forbes JF; Dowsett M; Knox J; Cawthorn S; Saunders C; Roche N; Mansel RE; von Minckwitz G; Bonanni B; Palva T; Howell A;
    Lancet; 2014 Mar; 383(9922):1041-8. PubMed ID: 24333009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
    Mok CC; Tong KH; To CH; Siu YP; Ma KM
    Osteoporos Int; 2008 Mar; 19(3):357-64. PubMed ID: 18038273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial.
    Sestak I; Blake G; Patel R; Cuzick J; Howell A; Coleman R; Eastell R
    Br J Cancer; 2021 Apr; 124(8):1373-1378. PubMed ID: 33495601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
    Forbes JF; Sestak I; Howell A; Bonanni B; Bundred N; Levy C; von Minckwitz G; Eiermann W; Neven P; Stierer M; Holcombe C; Coleman RE; Jones L; Ellis I; Cuzick J;
    Lancet; 2016 Feb; 387(10021):866-73. PubMed ID: 26686313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.
    Greenspan SL; Brufsky A; Lembersky BC; Bhattacharya R; Vujevich KT; Perera S; Sereika SM; Vogel VG
    J Clin Oncol; 2008 Jun; 26(16):2644-52. PubMed ID: 18427147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Reid DM; Devogelaer JP; Saag K; Roux C; Lau CS; Reginster JY; Papanastasiou P; Ferreira A; Hartl F; Fashola T; Mesenbrink P; Sambrook PN;
    Lancet; 2009 Apr; 373(9671):1253-63. PubMed ID: 19362675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.
    Hines SL; Mincey BA; Sloan JA; Thomas SP; Chottiner E; Loprinzi CL; Carlson MD; Atherton PJ; Salim M; Perez EA
    J Clin Oncol; 2009 Mar; 27(7):1047-53. PubMed ID: 19075260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II).
    Jenkins VA; Ambroisine LM; Atkins L; Cuzick J; Howell A; Fallowfield LJ
    Lancet Oncol; 2008 Oct; 9(10):953-61. PubMed ID: 18768369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial.
    Cuzick J; Chu K; Keevil B; Brentnall AR; Howell A; Zdenkowski N; Bonanni B; Loibl S; Holli K; Evans DG; Cummings S; Dowsett M
    Lancet Oncol; 2024 Jan; 25(1):108-116. PubMed ID: 38070530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.